Historical Valuation
Anavex Life Sciences Corp (AVXL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.64. The fair price of Anavex Life Sciences Corp (AVXL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：4.29
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Anavex Life Sciences Corp (AVXL) has a current Price-to-Book (P/B) ratio of 3.36. Compared to its 3-year average P/B ratio of 5.23 , the current P/B ratio is approximately -35.69% higher. Relative to its 5-year average P/B ratio of 6.68, the current P/B ratio is about -49.67% higher. Anavex Life Sciences Corp (AVXL) has a Forward Free Cash Flow (FCF) yield of approximately -11.87%. Compared to its 3-year average FCF yield of -5.43%, the current FCF yield is approximately 118.73% lower. Relative to its 5-year average FCF yield of -4.41% , the current FCF yield is about 169.00% lower.
P/B
Median3y
5.23
Median5y
6.68
FCF Yield
Median3y
-5.43
Median5y
-4.41
Competitors Valuation Multiple
AI Analysis for AVXL
The average P/S ratio for AVXL competitors is 0.00, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AVXL
1Y
3Y
5Y
Market capitalization of AVXL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AVXL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AVXL currently overvalued or undervalued?
Anavex Life Sciences Corp (AVXL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.64. The fair price of Anavex Life Sciences Corp (AVXL) is between to according to relative valuation methord.
What is Anavex Life Sciences Corp (AVXL) fair value?
AVXL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Anavex Life Sciences Corp (AVXL) is between to according to relative valuation methord.
How does AVXL's valuation metrics compare to the industry average?
The average P/S ratio for AVXL's competitors is 0.00, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Anavex Life Sciences Corp (AVXL) as of Jan 09 2026?
As of Jan 09 2026, Anavex Life Sciences Corp (AVXL) has a P/B ratio of 3.36. This indicates that the market values AVXL at 3.36 times its book value.
What is the current FCF Yield for Anavex Life Sciences Corp (AVXL) as of Jan 09 2026?
As of Jan 09 2026, Anavex Life Sciences Corp (AVXL) has a FCF Yield of -11.87%. This means that for every dollar of Anavex Life Sciences Corp’s market capitalization, the company generates -11.87 cents in free cash flow.
What is the current Forward P/E ratio for Anavex Life Sciences Corp (AVXL) as of Jan 09 2026?
As of Jan 09 2026, Anavex Life Sciences Corp (AVXL) has a Forward P/E ratio of -7.67. This means the market is willing to pay $-7.67 for every dollar of Anavex Life Sciences Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Anavex Life Sciences Corp (AVXL) as of Jan 09 2026?
As of Jan 09 2026, Anavex Life Sciences Corp (AVXL) has a Forward P/S ratio of 0.00. This means the market is valuing AVXL at $0.00 for every dollar of expected revenue over the next 12 months.